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The macroliderapamycin (RAP) is a potent inhibitor
of interleukin-2 (IL-a)-inducedT-cell proliferation.
Current models suggest that RAP, when complexed to
its intracellular receptor, FK506-binding protein, interferes withan IL-2 receptor-coupledsignaling pathway required for cell-cycle progression from G1- to Sphase. Here we show that RAP treatment inhibits the
growth of an IL-2-dependent cytotoxic T-cell line,
CTLL-2, in late G1-phase, just prior to entry of the
cells into S-phase. In contrast, RAP-treated CTLL-2
cells retained the ability to respond to IL-2 with enhanced cytolytic activity, indicating that RAP was not
a general suppressant of cellular responsiveness to IL2. Subsequent studies revealed that IL-2 stimulation
triggered a delayed activation of the ~ 3 4 " kinase,
~ " ~
the timing of which correlated with the G1- to S-phase
transition. The IL-2-dependent increase in ~ 3 4 "ki~ "
nase activity was blocked by RAP.The RAP sensitivity
of the ~ 3 4 "activation
~ " ~
mechanism implicates this signaling pathway in the control of S-phase commitment
in IL-2-stimulated T-cells.

prolyl isomerase inhibition does not explain the immunosuppressive actions of these drugs (3). In the case
of FK506,
biochemical and genetic evidence supports a gain-of-function
model in which theFK506-FKBP complex bindstoand
inhibits the activity
of the CaZf/calmodulin-dependent serinethreonine phosphatase calcineurin (4-8). According to this
model, calcineurincatalyzes a criticaldephosphorylation
event leading to the transcriptional activation of the IL-2
gene in antigen-stimulated T-cells.
Theantiproliferative effects of RAP also appearto be
exerted throughcomplex formation with FKBP (9).
Although
a direct targetfor the active RAP. FKBPspecies has notbeen
defined, this complex apparently inhibitsa biochemical event
that is necessary for the progression of IL-2-stimulated T cells from G1- to S-phase (10, 11). Recent studies have de~
scribeda RAP-sensitivesignaltransductionpathwaythat
leads to the phosphorylation and catalytic activationof p70
S6 kinase ingrowth factor-stimulated T-cells and fibroblasts
(12-15). However, the role of p70 S6 kinase inhibition in T cell growth suppression by RAP is unclear.
In eukaryotic cells, both the GI- to S-phase andGz- to Mphase transitions are controlled by highly conserved regulatory cascades. The central components of both cascades are
The immunosuppressive macrolides FK506 and rapamycin the cyclins and their associated cyclin-dependent kinases,of
(RAP)' inhibit T-cell-dependent immune responses by inter- which ~34'~'' is the prototype (16,17). In actively cycling
fering with signal transduction pathways essential for anti- cells, ~ 3 4 ' ~ protein
"'
levels are relatively invariant, whereas
gen-induced T-cell activation andgrowth (1).FK506 inhibits ~34'~'' kinaseactivityfluctuatesin
a cell cycle-dependent
a Ca2+-dependentsignaling event involved in the coupling of fashion. The periodicity of ~ 3 4 " ~ "kinase
'
activity reflects
T-cell antigen receptor ligation to the expression of a subset transient complex formation withspecific cyclin family memof lymphokine genes, including the interleukin-2 (IL-2)gene. bers aswell as changes in the phosphorylation state
of p34'd'2
Although structurally related to FK506, RAP targets a dis- itself. Genetic analyses in budding yeast have clearly estabtinct step in the T-cell activation program,i.e. the prolifera- lished the importanceof ~ 3 4 " ~kinase
"
activationin triggering
tive response of activated T-cells to the autocrine- or para- both the GI- to S-phase and Gz- to M-phase transitions
(18).
crine-acting growth factor IL-2.
In higher eukaryotes, the mitoticrole of p34'd'2 is well-docuThe molecular mechanismsunderlyingtheimmunosupmented. Although the requirement for ~34'~'' kinase activapressive effects of FK506 and RAP areonly partially under- tion in S-phasecommitment is less clear, several reports
stood. Both drugs interact witha family of cytosolic proteins, implicate ~ 3 4 " ~in"G1/S-phase regulation in mammaliancells
termed FKBPs, that expresspeptidylprolyl isomerase activi- (19-22).
ties (2). Binding of FK506 or RAP inhibits the FKBP-assoIn this study,we have examined the effects of RAP on ILciated peptidylprolylisomeraseactivity;
however, peptidyl- 2-dependent cell-cycle progression using a highly defined T * This work was supported by the Mayo Foundation andby Grant cell growth model system, the murine CTLL-2 cell line. Our
growth of these cells
DCB-8616001 from the National Science Foundation. The costs of results indicate that RAP arrests the
boundary. Evidence is presented that the
publication of this article were defrayed in part by the payment of near the G1/S-phase
page charges. This article must therefore be hereby marked "aduerRAP-induced inhibition of S-phase entry is related to the
tisement" in accordance with 18U.S.C. Section 1734 solely to indicate inhibition of thelate G1-phase increase in ~ 3 4 ' ~ ' kinase
'
this fact.
activity normally induced by cellular stimulation with IL-2.

I( Leukemia Society of America Scholar. T o whom correspondence
should be addressed Dept. of Immunology, Rm. 342B-Guggenheim,
Mayo Clinic,Rochester, MN 55905. Tel.: 507-284-4095; Fax: 507284-1637.
The abbreviations used are: RAP, rapamycin; IL-2, interleukin2; FKBP, FK506-binding protein; [3H]dThd,[methyl-3H]thymidine.

MATERIALSANDMETHODS

Cells-The murine IL-2-dependent cytotoxic T-cell line CTLL-2
(23) was obtained from the American Type CultureCollection. CTLL2 cells were maintained in basal medium (RPMI 1640 medium con-
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taining 10% (v/v) fetal bovine serum, 2 mM L-glutamine, 50 p M 2mercaptoethanol and buffered to pH 7.2 with 10 mM HEPES) SUPplementedwith10%(v/v)ratsplenocyte-conditioned
medium (a
source of T-cell growth factor) and 5 units/ml recombinant human
IL-2.
The hamster hybridoma B-cell line 145-2C11 (24) was the kind
gift of Dr. Jeffrey Bluestone (University of Chicago, Chicago). Prior
t o use in cytotoxicity assays, the cells were sorted for high surface
expression of immunoglobulin specific for the CD3-t subunit of the
T-cell antigen receptor. Hydridoma cells were routinely passaged in
basal medium.
Reagents and Antibodies-Recombinant human IL-2 was generously provided by Hoffmann-La Roche. Histone type 111-S was obtained from Sigma. Rabbit polyclonal antiserum directed against the
carboxyl-terminal sequence (CDNQIKKM) of the ~ 3 4 ' polypeptide
~'~
(25) was the kind gift of Dr. Edward Leof (Mayo Clinic, Rochester,
MN). Unless otherwise indicated, other reagents were obtained from
standard commercial suppliers.
DNA Synthesis Assays-Growth factor-inducedDNAsynthesis
wasquantitated by measurement of [methylL3H]thymidine([3H]
dThd) incorporation as previously described (26). Briefly, triplicate
microcultures were prepared in 96-well plates. After 18 h in culture,
each sample well was pulsed with 1 WCi of [3H]dThd, and samples
were harvestedonto glassmicrofiber filters at 24 h. Radiolabeled
DNA was assayed by liquid scintillation counting.
Cell-cycle Analysis-Cells were harvested by centrifugation and
fixed in 95% ethanol. The fixed cells were treated with 100 pg/ml
RNase A for 30 min a t 37 "C. Cellular DNA was stained by treating
t he cells with 20 pg/ml propidium iodide for 20 min, and fluorescence
was quantitated on a per cell basis by flow cytofluorometry.
Cytotoxicity Assay-The T-cell antigen receptor-dependent cytolytic activity of CTLL-2 cells toward the anti-CD3-t antibody-expressing targetcell line 145-2C11 was assayed as described previously
(27). Briefly, CTLL-2 effector cells were cultured in IL-2-free basal
medium for 12 h, and the factor-deprived cells were incubated for 1
h with basalmediumonly orbasal medium containing
M RAP.
Recombinant IL-2 (50 units/ml) was added to the indicated samples,
and the cells were cultured an additional 4 h. Finally, the pretreated
effector cells were coculturedfor4h
with 51Cr-labeled 145-2C11
target cells, and specific 51Cr release was measured intriplicate
samples asdescribed (28).
Northern Hybridization-Total cellular
RNA was isolated using
t he RNazole B reagent (Biotecx, Inc., Friendsville, T X ) according to
the manufacturer's instructions. RNA (30 pglsample lane) was electrophoresedthrough a formaldehyde-containing 0.6% agarose gel.
After transfer toa Hybond N membrane (AmershamCorp.), the RNA
was successively hybridized with 32P-labeled c-Jun, c-myc, and glyceraldehyde-3-phosphate dehydrogenase DNA probes. Hybridizing
species were detected by autoradiography at -70 "C with Quanta 111
intensifying screens (Du Pont-New England Nuclear).
DNA Probes-DNA probes were prepared by labeling of the indicated plasmid DNA inserts with [o-32PJCTP toa minimum specific
activity of 5 X 10' cpmlpg DNAusing a random oligomer priming kit
(PharmaciaLKB Biotechnology Inc.). The c-Jun probe wasa 2kilobase EcoRI fragment from plasmid JAC7 (29). The c-myc probe
was a 0.98-kilobase XbaI-Sac1 fragment from pSVC-MYC-1 (30).
The
glyceraldehyde-3-phosphatedehydrogenase probe was a 1.85-kilobase
PstI fragment from pIBI3O-GAPDH, which was kindly provided by
Dr. S. Kang (Mount SinaiMedical Center, New York).
Histone Phosphorylation Assay-Cells were cultured in basal medium for 12 h. The growth factor-deprived cells were transferred to
basal medium containing 1 mM hydroxyurea and 50 units/ml IL-2.
Either RAP was added at the timeof culture initiation (0 h), or drug
addition was delayed to 13 h. Cells were harvested at 14 h; washed
one time with phosphate-buffered saline (pH7.2) containing 0.5 mM
EDTA; and lysed in 20 mM Tris-HC1, 30 mM Na4PZO7,50 mM NaF,
5 mM EDTA (pH 7.2) containing 0.5% Triton X-100, 1 mM dithiothreitol, 10 pg/ml leupeptin, 5 pg/ml aprotinin, and 10 mM P-glycerophosphate. The lysates were cleared of insoluble material by centrifugation. The concentration of detergent-soluble protein was determined by the method of Bradford (31), and equal amounts
of
protein (250 pg/sample) were immunoprecipitated a t 4 "C with
p34'dc2-specific antiserum and protein A-coupled Sepharose beads.
After 45 min, the immunoprecipitates were washed two times with
lysis buffer, followed by two washeswithkinasebuffer(20
mM
HEPES (pH 7.0), 10 mM &glycerophosphate, 6 mM MgC12, 10 pg/ml
leupeptin, and 1 mM dithiothreitol). Histonephosphorylation was
initiated by addition of 40 pl of kinase buffer containing 1p~ [y"P]

p34'dc2
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ATP (specific activity, 1.25 Ci/mmol) and 0.6 mg/ml histone. After
10 min at 37 "C, the phosphorylation reaction
was terminated with 1
volume of ice-cold 20 mM EDTA (pH 8.0). Duplicate aliquots of the
samplesupernatant
were spottedonto
phosphocellulose papers
(Whatman, Inc., Maidstone,UnitedKingdom).Thepapers
were
immersed in 1%HaPO, solution containing 10 mM NG'20,. After
three additional 15-min washes in 1% &PO,, radioactivity incorporated into the filter-bound histone
was assayed by liquid scintillation
counting.
Immunoblot Analysis-After the histone phosphorylation assay,
the ~34'~'' immunoprecipitateswere washed with 100 mM Tris-HCI
(pH 7.2) containing 500 mM LiCl. The proteins were solubilized a t
100 "C in reducing Laemmli sample buffer (32) and separated by
SDS-polyacrylamide gel electrophoresis through a 10% gel. The proteins were transferred electrophoretically to an Immobilon P membrane. To enhance immunoreactivity, the blotted proteinswere subjected t o a denaturation-renaturation procedure described previously
(33). The membranes were blocked in Tris-buffered saline (25 mM
Tris-HC1(pH 7.2), 150 mM NaCl)containing 2% bovine serum
albumin and0.5% Tween 20. The blotted proteins were subsequently
probed with a 1:250 dilution of p34cd'2-specific antiserum in Trisbuffered saline containing 0.5% Tween 20. Immunoreactive proteins
were detected with proteinA-coupled horseradish peroxidase and the
enhanced chemiluminescence detection reagent (ECL) from Amersham Corp.
RESULTS ANDDISCUSSION

The murine cytotoxic T-cell line CTLL-2 exhibits strict
dependence on exogenous IL-2 for maintenance of both viability and continuous proliferation in culture. In preliminary
experiments, we evaluated the sensitivityof these cells to the
antiproliferative effect of RAP. These studies demonstrated
that themaximal increase in DNA synthesisinduced by IL-2
was progressivelyinhibited by RAP a t concentrations ranging
from 3 X lo-" to 1 X IO-' M (data not shown). As shown in
Fig. 1 (left panel), treatment of CTLL-2 cells with lo-' M
RAP reduced IL-2-stimulated [3H]dThd incorporation into
newly synthesized DNA by 50-70% over the entire range of
growth factorconcentrationstestedinthese
studies. The
growth-suppressive actions of RAP were not explained by a
drug-induced reduction incell viability as measured by trypan
blue dye exclusion (data not shown). Furthermore, the inhibitory effect of RAP on IL-2-stimulated DNA synthesis was
completelyreversed by a100-foldmolarexcess
of FK506,
indicating that the RAP-induced inhibition of CTLL-2 cell
growth was mediatedthroughbindingtoanintracellular
FKBP (10, 11).
In subsequent experiments, CTLL-2 cells were exposed to
RAP at various times after addition of IL-2 (Fig. 1, right
panel). The IL-2-dependent increase in DNA synthesis remained fully sensitive to RAPfor at least 12 hafter the initial
stimulation with growth factor. These datasuggest that RAP
interferes witha relatively distal regulatory event required for
the entryof IL-%stimulated CTLL-2 cells into S-phase.
In addition to its growth-promoting activity, IL-2 stimulates both the differentiation and effector functions of activated T-cells(34,35). In recent studies,we demonstrated that
theT-cellantigenreceptor-dependent
cytolytic activity of
CTLL-2 cells is strongly increased by prior exposure of the
cells to IL-2 (27). Although the underlying mechanism remains unclear, others have shown that the enhancement of
cytolytic function by IL-2 requires new protein synthesis, but
not DNA replication (35). The results inFig. 2 demonstrated
that lo-' M RAP had no effect on either the basal or IL-2enhanced cytolytic activities of CTLL-2 cells. Thus,RAP
interfered with IL-2-dependent mitogenic signaling without
inducing a generalized suppression of cellular responsiveness
to IL-2.
Stimulation of activated murine T-cells with IL-2 induces
expression of several early response genes, including c-myc
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FIG.1. Effects of RAP on growth factor-stimulated DNA synthesis. k j t panel, IL-2-stimulated CTLL-2 cell growth. Cells were
harvested from complete growth medium and resuspended in IL-2-free basal medium. Cells were plated in microtiter wells (lo‘ cells/well)
and cultured in the presence of the indicated concentrations of IL-2. RAP (lo-’ M ) and FK506 (lo-’ M ) were added at the timeof culture
initiation. After 18 h, the cultures were pulsed with 1 pCi/welI [3H]dThd. Cells were harvested a t 24 h, and radioactivity incorporated into
DNA was quantitated by liquid scintillation counting. Data points and error bars represent [’HIdThd incorporation (mean cpm S.E., n =
3) into cellular DNA. Right panel, delayed addition of RAP. CTLL-2 cells were cultured and analyzed as described above, except that lo-’ M
RAP was added at theindicated times after cellular stimulation with IL-2.
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FIG.2. Effect of RAP on basal and IL-2-enhanced cytolytic
activities. CTLL-2 cells were cultured in basal medium for 12h.
Growth factor-deprived cells were plated a t varying cell densities in
microtiter wells, and theindicated samples were pretreated with
M RAP for 1 h. The pretreated cells were cultured for an additional
4 h in the absence or presence of 50 units/ml IL-2. Cytotoxicity assays
were initiated by adding IO‘ ”Cr-labeled target cells to each well.
After 4 h, target cell lysis was assessed by measurement of 61Crrelease
into theculture supernatant.Data pointsrepresent mean specific “Cr
release from triplicate samples. Coefficients of variation were 1 6 %
of the mean.

FIG.3. Effect of RAP on IL-2-induced early gene expression. First through fourth lanes, CTLL-2 cells were cultured in basal
medium for 8 h prior to addition of lo-’ M RAP to the indicated
samples. After 4 h, cells were stimulated with medium only or 50
units/ml IL-2. Fifth and sixth lanes, exponentially growing CTLL-2
cells were cultured for 12 h in basal medium containing 50 units/ml
IL-2 in the absence (-) or presence (+) of lo-’ M RAP. Total cellular
RNA was isolated as described under “Materialsand Methods.” RNA
blots were sequentially hybridized with 32P-labeled probes for the
indicated RNA transcripts. The glyceraldehyde-3-phosphate dehydrogenase (GAPDH)probe was used to control for variations in RNA
loading among individual sample lanes.

treated culture (see Table I). Thus, RAP did not interfere
with the IL-2 receptor-coupled signaling pathway leading to
expression of the c-myc and c-jungenes in CTLL-2 cells.
The above observations were consistent with the possibility
that the antiproliferative effect of RAP was exerted in late
and c-jun (36, 37). Previous studies have shown that inhibi- G1-phase. Both cell-cycle analysis (Fig. 4, left panel) and [3H]
tion of IL-2-stimulated c-myc mRNAaccumulation in T-cells dThd pulse experiments (data not shown) demonstrated that
is correlated with the suppression of cell growthby transform- factor-deprived CTLL-2 cells required -11-12 h to traverse
ing growth factor-@(37) and cyclic AMP (38). Consequently, G1-phase after restimulation with IL-2. To moreprecisely
we examined the effects of RAP treatment on the accumula- define the G1-phase arrest state induced by RAP, CTLL-2
tion of c-jun and c-myc mRNAtranscripts in IL-2-stimulated cells were cultured for 12 h in the presence of IL-2 and RAP
CTLL-2 cells. After a 1-h exposure to growth factor, IL-2- (Table I). The cells were then released from RAP-induced
deprived CTLL-2 cells exhibited marked increases in c-jun growth arrest by washing and resuspension in IL-2-suppleM FK506.ExcessFK506was
and c-myc mRNA levels (Fig. 3, first and second lanes). The mented medium containing
rapid accumulation of c-myc and c-junmRNAs wasunaffected added to competitively displace any residual RAP fromintraby pretreatment of these cells with lo-’ M RAP for 4 h prior cellular FKBPs. At 2-h intervals after releasefromRAPto addition of IL-2 (third and fourth lanes). Moreover, pro- induced growth arrest, the cells were analyzed forDNA conlonged (12-h) exposure of asynchronously cycling CTLL-2 tent by propidium iodide staining or were pulsed with [3H]
cells to RAP had noeffect on the steady-statelevels of c-myc dThd to determine the onset ofnewDNA synthesis. The
and c-jun mRNA transcripts (fifth and sixth lanes), in spite RAP-treated cells entered S-phase in a relatively synchronous
of the progressive accumulation of G1-phase cells in
the drug- fashion at 2-4 h after release, indicating that drug exposure
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FIG. 4. Effect of RAP on IL-2-dependent ~ 3 4 *kinase
~
activation. Left panel, activation of ~ 3 4 ~kinase
"
during GI- to S-phase
transition in IL-2-stimulated cells. CTLL-2 cells were cultured in basal medium for 12 h to induce early G,-phase growth arrest. Factordeprived cells were stimulated with 50 units/ml IL-2 for the indicated times, and samples were analyzed for percentages of cells with GIphase (0)and S-phase (0)DNA contents by propidium iodide staining. p34dcz-specifichistone H1 kinase activities).( were measured in
parallel samples. Cell populations used for ~ 3 4 kinase
~ " assays were treated with hydroxyurea to block progression into S-phase. Samples (2
X lo6 cells) were withdrawn at theindicated times, and detergent-soluble proteins were immunoprecipitated with p34cd'2-specificantibodies.
Protein kinase assays measured the incorporation of radiolabel from [y-32P]ATP into thehistone H1 substrate. Data points represent the
results of duplicate determinations a t each time point.Right panel, RAP inhibition of ~ 3 4 kinase
~ "
activation.Factor-deprived CTLL-2 cells
were cultured for 14 h in basal medium only (bar I ) , 50 units/ml IL-2 (bar 2 ) , 50 units/ml IL-2 plus lo-' M RAP (bar 3 ) , or 50 units/ml IL2 with lo-' M RAP added during the final hour of culture (bar 4 ) . All treatments were performed in the presence of hydroxyurea. ~ 3 4 ~ " specific histone H1 kinase activity was assayed as described above, except that cell extracts were normalized for protein content (250 pg/
sample) prior to immunoprecipitation. Bars and error flags represent means f S.D. of three independent experiments. After removal of the
kinase reaction buffer, the immune complexes were solubilized in SDS-containing sample buffer, and proteins were separated by SDSpolyacrylamide gel electrophoresis. Proteins were transferred to Immobilon P (Millipore) and probed with a n t i - ~ 3 4 ~antiserum.
"
Immunoreactive species were detected using a chemiluminescence detection system. The inset shows a representative ~34'~''immunoblot from one of
the ~ 3 4 kinase
~ " activity assays used to generate the data in the main part of the figure.

TABLE
I
inhibition of ~ 3 4 ' ~synthesis
'~
blocks the proliferation of huS-phase entry afterRAP-induced growtharrest
man T lymphocytes at the G1/S-phase border. Based on our
CTLL-2 cells were precultured for 12 h in basalmedium containing finding that RAP treatment blocked IL-%stimulated CTLL50 units/ml IL-2 and drug vehicle only (-RAP) or lo-' M RAP. At t 2 cell growthat a similar point in the cell cycle,we speculated
= 0 h, the cells were stained with propidium iodide, and cell-cycle
that these cells might exhibit an increase in p3FdC2kinase
distributions were analyzed with a fluorescence-activated cell sorter.
The remaining RAP-treated cells were washed and resuspended in activity in late G1-phaseand that thisbiochemical event could
basal medium (1.5 X 10' cells/ml) containing 50 units/ml IL-2 and represent an important targetfor T-cell growth inhibition by
lo-' M FK506. Aliquots (200 pl) were removed and pulsed a t 2-h RAP.
intervals with 2 pCi of t3H]dThd. Parallel samples were fixed at the
Initial studies examined the effects of IL-2 on ~ 3 4 ' ~ ' ~ indicated times and stained with propidium iodide for cell-cycle specific histone H1 kinase activity in cells arrested in early
analysis by flow cytofluorometry.
G1-phaseby growth factor deprivation (Fig. 4, leftpanel).The
Time post FK506
[3H]dThd incorporation
GI
S

cellswere treated with hydroxyurea to blockprogression
through S-phase, thereby ensuring that any observed changes
-RAP, 0
41
36
in histone H1 kinase activity were not due to ~ 3 4 ' ~isolated
'~
+RAP
from contaminating G2/M-phasecells. The histone H1 kinase
0
65
25
activity of p3FdC2remained at basal levelsfor 8 hafter
2
2.07 k 1.19
60
23
restimulation of factor-deprived cells with IL-2 andthen
4
14.53 -t 1.83
50
31
6
21.81 f 3.93
50
36
increased abruptly at 8-10 h aftergrowth factor addition. The
8
27.07 k 3.19
44
35
initial burst of ~ 3 4 ' ~kinase
'~
activity immediately preceded
the transition of the growth factor-stimulated cell population
~ ' ~was not
arrests IL-2-dependentcell-cycle progressionin late G1-phase. from G1- to S-phase. Activation of the ~ 3 4 kinase
contingent
on
DNA
replication
because
an
identical
time
In fact, the actual cell-cycle arrest point may more closely
course
of
enzyme
activation
was
obtained
in
the
absence
or
approximate the G1/S-phase border given that the drug release protocol probably fails to induce an immediate reversal presence of hydroxyurea (data not shown).
To determine whether the late G1-phase increase in ~ 3 4 ' ~ ' ~
of the cellular actions of RAP.
Previous studies have implicated members of the cyclin and kinase activity was sensitive to RAP, hydroxyurea-treated
cyclin-dependent kinase families as universal regulators of CTLL-2 cellswere stimulated with IL-2 for 14 h in the
the G1- to S-phase and G2- to "phase transitions in the absence or presence of lo-' M RAP (Fig. 4, right panel). The
' ~ activity induced by IL-2 was
eukaryotic cell cycle (16, 17). Relatively little is known con- delayed increase in ~ 3 4 ' ~kinase
cerning the molecular events that commit IL-2-stimulated T- strongly suppressed when RAP wasadded at the time of
cells to enter S-phase. However, Furukawa et al. (20) used an culture initiation. In contrast, when drug addition was postantisense oligonucleotide-basedapproach to demonstrate that poned to the final hour of culture, RAP had no effect on
h

Akcpm f S.D.

%

%
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~ 3 4 ' ~ 'activity,
'
suggesting that, once activated, the protein
biochemical pathways emanatingfrom a commonRAP-inhibkinase was insensitive to this drug. The inhibitory effect of itable molecular event. Further studiesusing RAP asa probe
RAP on the activation
of ~ 3 4 " ~was
" FKBP-dependent as this will provide novel insights into the signal transduction patheffect was completely abrogated by the simultaneous addition way responsible for S-phase commitment in IL-2-stimulated
T-cells.
of a 100-fold molar excess of FK506 (data not shown). Immunoblot analysis demonstrated that IL-2 stimulation had
Acknowledgments-We thank L. Karnitz and E. Leof for review of
no effect on the level of immunoprecipitable p3YdC2protein,
manuscript and E. Leof for providing the p34'd'2-specific antiindicating that the observed changes in histone H1 kinase the
serum.
activity reflected growth factor-dependent alterations in the
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